Antiangiogenic agents in natural products for the treatment of gynecologic disorders

Azar Aghamohammadi, Seyed Jalal Hosseinimehr
Nutrition and cancer · 2014 · vol. 66(2) , pp. 206–213 · doi:10.1080/01635581.2014.865136 · PMID:24410431 · W2002960776
Review OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This review focuses on natural products with antiangiogenic activity for treating gynecologic disorders like endometriosis and uterine fibroids by inhibiting vascular endothelial growth factor.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Angiogenesis is the formation of new capillaries from existing vessels. Vascular endothelial growth factor (VEGF) promotes this growth by stimulating endothelial cells, which form vessel walls and transport nutrients and oxygen to tissues. VEGF has been implicated in several diseases, such as cancer and gynecologic disorders. Antiangiogenic agents prevent VEGF from binding to its receptors on the endothelial cell surface, which inhibits vessel development. Antiangiogenic agents have been found to be effective in treating several gynecologic diseases, such as endometriosis and uterine fibroids. Natural products with respect to finding new compounds with antiangiogenic effects are interested. In this review, we have focused on the importance of natural products with antiangiogenic activity in treating some malignant and benign angiogenesis-related gynecological disorders, including endometriosis and uterine fibroids.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Angiogenesis Inhibitors Biological Products Genital Diseases, Female Genital Neoplasms, Female Neovascularization, Pathologic Angiogenesis Inhibitors Angiogenesis Inhibitors Animals Animals Biological Products Biological Products Disease Models, Animal Disease Models, Animal Female Female Genital Diseases, Female Genital Diseases, Female Genital Neoplasms, Female Genital Neoplasms, Female Humans

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (100)

Cited by (1)

Source provenance

europepmc
last seen: 2026-10-12T06:17:10.165071+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T21:13:06.373426+00:00
unpaywall
last seen: 2026-10-12T06:33:14.382917+00:00
License: CC0 · commercial use OK